BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 20140431)

  • 1. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.
    Olson BM; Frye TP; Johnson LE; Fong L; Knutson KL; Disis ML; McNeel DG
    Cancer Immunol Immunother; 2010 Jun; 59(6):943-53. PubMed ID: 20140431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes.
    Johnson LE; McNeel DG
    Prostate; 2012 May; 72(7):730-40. PubMed ID: 22529020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells.
    Olson BM; McNeel DG
    Cancer Immunol Immunother; 2011 Jun; 60(6):781-92. PubMed ID: 21350948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
    Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer.
    Becker JT; Olson BM; Johnson LE; Davies JG; Dunphy EJ; McNeel DG
    J Immunother; 2010; 33(6):639-47. PubMed ID: 20551832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of prostate-specific G-protein coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer immunotherapy.
    Matsueda S; Wang M; Weng J; Li Y; Yin B; Zou J; Li Q; Zhao W; Peng W; Legras X; Loo C; Wang RF; Wang HY
    PLoS One; 2012; 7(9):e45756. PubMed ID: 23029225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of human MHC-I HPV18 E6/E7-specific CD8 + T cell epitopes and generation of an HPV18 E6/E7-expressing adenosquamous carcinoma in HLA-A2 transgenic mice.
    Peng S; Xing D; Ferrall L; Tsai YC; Hung CF; Wu TC
    J Biomed Sci; 2022 Oct; 29(1):80. PubMed ID: 36224625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice.
    Saif JM; Vadakekolathu J; Rane SS; McDonald D; Ahmad M; Mathieu M; Pockley AG; Durrant L; Metheringham R; Rees RC; McArdle SE
    Eur J Immunol; 2014 Apr; 44(4):994-1004. PubMed ID: 24338683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of T helper epitopes from prostatic acid phosphatase.
    McNeel DG; Nguyen LD; Disis ML
    Cancer Res; 2001 Jul; 61(13):5161-7. PubMed ID: 11431355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201-restricted CD8+ T cells in HLA-transgenic mice and humans.
    Geluk A; van Meijgaarden KE; Franken KL; Drijfhout JW; D'Souza S; Necker A; Huygen K; Ottenhoff TH
    J Immunol; 2000 Dec; 165(11):6463-71. PubMed ID: 11086086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses.
    Smith HA; Rekoske BT; McNeel DG
    Vaccine; 2014 Mar; 32(15):1707-15. PubMed ID: 24492013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation.
    Chakraborty NG; Stevens RL; Mehrotra S; Laska E; Taxel P; Sporn JR; Schauer P; Albertsen PC
    Cancer Immunol Immunother; 2003 Aug; 52(8):497-505. PubMed ID: 12783216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase.
    Klyushnenkova EN; Kouiavskaia DV; Kodak JA; Vandenbark AA; Alexander RB
    Prostate; 2007 Jul; 67(10):1019-28. PubMed ID: 17455230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.
    Smith HA; McNeel DG
    J Immunother; 2011 Oct; 34(8):569-80. PubMed ID: 21904219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells.
    Oh S; Terabe M; Pendleton CD; Bhattacharyya A; Bera TK; Epel M; Reiter Y; Phillips J; Linehan WM; Kasten-Sportes C; Pastan I; Berzofsky JA
    Cancer Res; 2004 Apr; 64(7):2610-8. PubMed ID: 15059918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model.
    Simons BW; Cannella F; Rowley DT; Viscidi RP
    Cancer Immunol Immunother; 2020 Apr; 69(4):641-651. PubMed ID: 32016503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Estimation of an NY-ESO-1 expressing HCC cell line by NY-ESO-1b specific CD8+T cells in vitro induced by HLA-A2 restricted NY-ESO-1b peptide].
    Qiao H; Qian XP; Zhang HG; Tian C; Chen WF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 37(6):565-8. PubMed ID: 16378102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice.
    Machlenkin A; Azriel-Rosenfeld R; Volovitz I; Vadai E; Lev A; Paz A; Goldberger O; Reiter Y; Tzehoval E; Benhar I; Eisenbach L
    Cancer Immunol Immunother; 2007 Feb; 56(2):217-26. PubMed ID: 16738849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
    Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
    J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine.
    Dangoor A; Lorigan P; Keilholz U; Schadendorf D; Harris A; Ottensmeier C; Smyth J; Hoffmann K; Anderson R; Cripps M; Schneider J; Hawkins R
    Cancer Immunol Immunother; 2010 Jun; 59(6):863-73. PubMed ID: 20043222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.